Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Caprelsa · 1 trial · 1 indication
To assess whether survival times for patients receiving gemcitabine plus vandetanib are longer than for those patients receiving gemcitabine alone as first line treatment for advanced pancreatic cancer
| Arm | Type | Description |
|---|---|---|
| Gemcitabine and Placebo | PLACEBO_COMPARATOR | Standard therapeutic arm. Placebo orally once a day continuously together with gemcitabine 1000mg/m2 weekly as a 30 minute infusion for 7 consecutive weeks. This will then be followed by a one week break and then gemcitabine 1000mg/m2 weekly as a 30 minute infusion for 3 weeks followed by a one week break in subsequent cycles. |
| Gemcitabine and vandetanib | EXPERIMENTAL | Experimental arm. Vandetanib orally once a day continuously together with gemcitabine 1000mg/m2 weekly as a 30 minute infusion for 7 consecutive weeks. This will then be followed by a one week break and then gemcitabine 1000mg/m2 weekly as a 30 minute infusion for 3 weeks followed by a one week break in subsequent cycles. |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Orally once a day, continuously throughout the study |
| Caprelsa (vandetanib) | DRUG | Orally once a daily, continuously throughout the study. |
Inclusion Criteria: * Age ≥ 18 years. * Histologically or cytologically proven pancreatic ductal adenocarcinoma or undifferentiated carcinoma of the pancreas. * Locally advanced or metastatic disease precluding curative surgical resection or definitive locally directed therapies such as chemo radia...
Top 20 of 68 competitors
Caprelsa is a small molecule being studied for the treatment of pancreatic cancer. It is currently in Phase 2 clinical development as an investigational therapy. The drug is being evaluated in combination with gemcitabine compared to gemcitabine alone in patients with pancreatic carcinoma.
Caprelsa, also known as vandetanib, is a small molecule that targets multiple receptor tyrosine kinases. It inhibits vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), and rearranged during transfection (RET) tyrosine kinase activity, which are involved in tumor growth and angiogenesis.
Caprelsa is being developed by AstraZeneca PLC, a multinational pharmaceutical company listed on the stock exchange under the ticker symbol AZN. The company is conducting clinical trials to evaluate the drug's efficacy and safety in pancreatic cancer.
Caprelsa is in Phase 2 clinical development for pancreatic cancer. It is an investigational drug and has not been approved by regulatory authorities for this indication. The Phase 2 trial has been completed, and the drug is no longer in active clinical trials for this condition.
Caprelsa has been studied in one completed Phase 2 clinical trial with the identifier NCT01601808. This randomized, double-blind, placebo-controlled trial enrolled 142 participants and compared gemcitabine plus vandetanib therapy with gemcitabine alone in patients with pancreatic carcinoma. The trial was conducted in the United Kingdom.
Yes, Caprelsa is the brand name for vandetanib. In clinical trials, the drug is referred to as vandetanib, and Caprelsa is the proprietary name used by the developer. Both names refer to the same small molecule being investigated for pancreatic cancer.